FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122861570> ?p ?o ?g. }

• W3122861570 endingPage "1505" @default.
• W3122861570 startingPage "1485" @default.
• W3122861570 abstract "To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer.ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options.A total of 41 articles met eligibility criteria and form the evidentiary basis for the guideline recommendations.Patients undergoing neoadjuvant therapy should be managed by a multidisciplinary care team. Appropriate candidates for neoadjuvant therapy include patients with inflammatory breast cancer and those in whom residual disease may prompt a change in therapy. Neoadjuvant therapy can also be used to reduce the extent of local therapy or reduce delays in initiating therapy. Although tumor histology, grade, stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should routinely be used to guide clinical decisions, there is insufficient evidence to support the use of other markers or genomic profiles. Patients with triple-negative breast cancer (TNBC) who have clinically node-positive and/or at least T1c disease should be offered an anthracycline- and taxane-containing regimen; those with cT1a or cT1bN0 TNBC should not routinely be offered neoadjuvant therapy. Carboplatin may be offered to patients with TNBC to increase pathologic complete response. There is currently insufficient evidence to support adding immune checkpoint inhibitors to standard chemotherapy. In patients with hormone receptor (HR)-positive (HR-positive), HER2-negative tumors, neoadjuvant chemotherapy can be used when a treatment decision can be made without surgical information. Among postmenopausal patients with HR-positive, HER2-negative disease, hormone therapy can be used to downstage disease. Patients with node-positive or high-risk node-negative, HER2-positive disease should be offered neoadjuvant therapy in combination with anti-HER2-positive therapy. Patients with T1aN0 and T1bN0, HER2-positive disease should not be routinely offered neoadjuvant therapy.Additional information is available at www.asco.org/breast-cancer-guidelines." @default.
• W3122861570 created "2021-02-01" @default.
• W3122861570 creator A5001315712 @default.
• W3122861570 creator A5002414152 @default.
• W3122861570 creator A5017334876 @default.
• W3122861570 creator A5022081423 @default.
• W3122861570 creator A5029049718 @default.
• W3122861570 creator A5032886944 @default.
• W3122861570 creator A5037198503 @default.
• W3122861570 creator A5040821779 @default.
• W3122861570 creator A5041183694 @default.
• W3122861570 creator A5052268581 @default.
• W3122861570 creator A5053489698 @default.
• W3122861570 creator A5070508240 @default.
• W3122861570 creator A5072004172 @default.
• W3122861570 creator A5075214231 @default.
• W3122861570 creator A5087559224 @default.
• W3122861570 creator A5088946926 @default.
• W3122861570 creator A5091772334 @default.
• W3122861570 date "2021-05-01" @default.
• W3122861570 modified "2023-10-13" @default.
• W3122861570 title "Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline" @default.
• W3122861570 cites W1045121760 @default.
• W3122861570 cites W1805599263 @default.
• W3122861570 cites W1955397179 @default.
• W3122861570 cites W1968602934 @default.
• W3122861570 cites W1987264721 @default.
• W3122861570 cites W1987326983 @default.
• W3122861570 cites W1991418795 @default.
• W3122861570 cites W1993114978 @default.
• W3122861570 cites W1995671931 @default.
• W3122861570 cites W2011683694 @default.
• W3122861570 cites W2024298772 @default.
• W3122861570 cites W2026457694 @default.
• W3122861570 cites W2032207130 @default.
• W3122861570 cites W2043506695 @default.
• W3122861570 cites W2046861708 @default.
• W3122861570 cites W2055235037 @default.
• W3122861570 cites W2058003857 @default.
• W3122861570 cites W2058585724 @default.
• W3122861570 cites W2075894019 @default.
• W3122861570 cites W2078386677 @default.
• W3122861570 cites W2084343791 @default.
• W3122861570 cites W2086064725 @default.
• W3122861570 cites W2087179076 @default.
• W3122861570 cites W2095633632 @default.
• W3122861570 cites W2096745115 @default.
• W3122861570 cites W2099152441 @default.
• W3122861570 cites W2101624340 @default.
• W3122861570 cites W2102773208 @default.
• W3122861570 cites W2107602135 @default.
• W3122861570 cites W2110222365 @default.
• W3122861570 cites W2111578514 @default.
• W3122861570 cites W2113242459 @default.
• W3122861570 cites W2114886164 @default.
• W3122861570 cites W2120349702 @default.
• W3122861570 cites W2121859894 @default.
• W3122861570 cites W2123591186 @default.
• W3122861570 cites W2123945948 @default.
• W3122861570 cites W2124623816 @default.
• W3122861570 cites W2125729597 @default.
• W3122861570 cites W2125794840 @default.
• W3122861570 cites W2127276782 @default.
• W3122861570 cites W2128822091 @default.
• W3122861570 cites W2129176838 @default.
• W3122861570 cites W2131915049 @default.
• W3122861570 cites W2136919572 @default.
• W3122861570 cites W2138014643 @default.
• W3122861570 cites W2139510434 @default.
• W3122861570 cites W2140974115 @default.
• W3122861570 cites W2144000726 @default.
• W3122861570 cites W2148330678 @default.
• W3122861570 cites W2151262170 @default.
• W3122861570 cites W2151552922 @default.
• W3122861570 cites W2154299562 @default.
• W3122861570 cites W2155560234 @default.
• W3122861570 cites W2156556190 @default.
• W3122861570 cites W2162760540 @default.
• W3122861570 cites W2162982444 @default.
• W3122861570 cites W2163403096 @default.
• W3122861570 cites W2164409215 @default.
• W3122861570 cites W2164774797 @default.
• W3122861570 cites W2165037690 @default.
• W3122861570 cites W2169351080 @default.
• W3122861570 cites W2169372049 @default.
• W3122861570 cites W2170915815 @default.
• W3122861570 cites W2171958606 @default.
• W3122861570 cites W2173764926 @default.
• W3122861570 cites W2193284631 @default.
• W3122861570 cites W2264815585 @default.
• W3122861570 cites W2304250174 @default.
• W3122861570 cites W2346232596 @default.
• W3122861570 cites W2346278060 @default.
• W3122861570 cites W2379981061 @default.
• W3122861570 cites W2394773016 @default.
• W3122861570 cites W2413636075 @default.
• W3122861570 cites W2467606258 @default.
• W3122861570 cites W2471493685 @default.

• next